Related references
Note: Only part of the references are listed.On the degrees of freedom in MCMC-based Wishart models for time series data
Yuewen Xiao et al.
STATISTICS & PROBABILITY LETTERS (2015)
Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints
Pei He
CONTEMPORARY CLINICAL TRIALS (2014)
Identifying Gene-Environment and Gene-Gene Interactions Using a Progressive Penalization Approach
Ruoqing Zhu et al.
GENETIC EPIDEMIOLOGY (2014)
A flexible observed factor model with separate dynamics for the factor volatilities and their correlation matrix
Yu-Cheng Ku et al.
STATISTICAL MODELLING (2014)
Adaptive enrichment designs for clinical trials
Noah Simon et al.
BIOSTATISTICS (2013)
Trial Designs for Personalizing Cancer Care: A Systematic Review and Classification
Parvin Tajik et al.
CLINICAL CANCER RESEARCH (2013)
Sample size and threshold estimation for clinical trials with predictive biomarkers
Howard M. Mackey et al.
CONTEMPORARY CLINICAL TRIALS (2013)
Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints
Xuemin Gu et al.
CONTEMPORARY CLINICAL TRIALS (2013)
Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research
Tze Leung Lai et al.
CONTEMPORARY CLINICAL TRIALS (2013)
A sequential testing approach to detecting multiple change points in the proportional hazards model
Pei He et al.
STATISTICS IN MEDICINE (2013)
MODELING LEFT-TRUNCATED AND RIGHT-CENSORED SURVIVAL DATA WITH LONGITUDINAL COVARIATES
Yu-Ru Su et al.
ANNALS OF STATISTICS (2012)
Personalized medicine using DNA biomarkers: a review
Andreas Ziegler et al.
HUMAN GENETICS (2012)
Recursively Imputed Survival Trees
Ruoqing Zhu et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2012)
Adaptive clinical trials in oncology
Donald A. Berry
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
MOMENT-BASED METHOD FOR RANDOM EFFECTS SELECTION IN LINEAR MIXED MODELS
Mihye Ahn et al.
STATISTICA SINICA (2012)
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Nicholas B. La Thangue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
Martin Jenkins et al.
PHARMACEUTICAL STATISTICS (2011)
STrengthening the Reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement
Valentina Gallo et al.
PLOS MEDICINE (2011)
Adjusted significance levels for subgroup analyses in clinical trials
Bart Spiessens et al.
CONTEMPORARY CLINICAL TRIALS (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)